<DOC>
	<DOCNO>NCT01154036</DOCNO>
	<brief_summary>This study compare lipid-altering efficacy safety switch co-administration ezetimibe atorvastatin versus treatment atorvastatin rosuvastatin high cardiovascular risk patient hypercholesterolemia achieve specified low-density lipoprotein cholesterol ( LDL-C ) level . The primary hypothesis co-administration ezetimibe 10 mg atorvastatin 10 mg superior atorvastatin 20 mg rosuvastatin 10 mg respect percentage reduction low-density lipoprotein-cholesterol ( LDL-C ) 6 week treatment .</brief_summary>
	<brief_title>MK0653C High Cardiovascular Risk Patients With High Cholesterol ( Switch Study ) ( MK-0653C-162 )</brief_title>
	<detailed_description>This 18 week randomize , double-blind , active-controlled , multicenter study compose 6 week screening/run-in 12 week double-blind treatment period ( composed 2 phase ; 6 week duration ) . Only participant meet low density lipoprotein-cholesterol ( LDL-C ) goal end Phase I ( Week 6 ) , eligible continue Phase II ( Week 12 ) .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patient high cardiovascular risk meet one follow condition : never take lipidlowering therapy therapy least 6 week ; , currently take stable dose certain lipidlowering agent Patient willing maintain cholesterol lower diet study Female patient receive noncyclical hormone therapy maintain stable dose regimen least 8 week willing continue regimen study Patient Asian Patient routinely 2 alcoholic drink per day Female patient pregnant breastfeeding Patient congestive heart failure Patient myocardial infarction , coronary bypass surgery , angioplasty , acute coronary syndrome within 3 month screen Patient uncontrolled cardiac arrhythmia Patient partial ileal gastric bypass significant intestinal malabsorption Patient uncontrolled high blood pressure Patient kidney disease Patient disease know influence blood lipid level Patient disorder blood , digestive system , nervous system include stroke degenerative disease would limit study participation Patient poorly control newly diagnose diabetes Patient know HIV positive Patient history cancer last 5 year , except certain skin cervical cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>